with draft physician labeling in hand and commercial readiness efforts well underway to support the successful launch ofneffyupon FDA approval,” stated Richard Lowenthal, Co-founder, President, and CEO of ARS Pharma. “We are also greatly encouraged by th...
The forward-looking statements included in this press release are made only as of the date hereof. ARS Pharma assumes no obligation and does not intend to update these forward-looking statements, except as required by law. ARS Pharma Investor Contact: Justin Chakma ARS Pharmaceuticals justinc@ars...
For more information, visit www.ars-pharma.com. Forward-Looking StatementsStatements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning o...
NeoImmuneTech said it signed an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH), to develop NT-I7 (ingredient: efineptakin alfa) to treat acute radiation syndrome (ARS). NeoImmuneTech CEO Yang Se-hwan ...
Drugs Big Pharma Exec Turned Whistleblower Criminal Inquiry Sought in Hillary Clinton’s Use of Email Hillary Blasts Reporters with LRAD White Noise Machine at Fundraiser So They Couldn't Hear Her American Imperialism’s Military Chaplains The US War on Your Passport – LewRock...
“We are pleased to announce that Aptar Pharma’s Unidose Powder System has been approved by the FDA for the first intranasally-delivered, needle-free rescue treatment for severe hypoglycemia that provides a more patient-friendly delivery approach. Our active packaging ...